Zinnat 125mg Film-Coated Tablets
- Name:
Zinnat 125mg Film-Coated Tablets
- Company:
GlaxoSmithKline (Ireland) Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/03/19
(Click to Download)Click on this link to Download PDF directly
GlaxoSmithKline (Ireland) Ltd
 Ltd.jpg)
Company Products
| Medicine Name | Active Ingredients |
|---|---|
| Medicine Name Zinnat 125mg/5ml Granules for Oral Suspension | Active Ingredients Cefuroxime Axetil |
| Medicine Name Zinnat 250mg Film-Coated Tablets | Active Ingredients Cefuroxime Axetil |
| Medicine Name Zinnat 250mg/5ml Granules for Oral Suspension. | Active Ingredients Cefuroxime Axetil |
| Medicine Name Zinnat 500mg Film-Coated Tablets | Active Ingredients Cefuroxime Axetil |
| Medicine Name Zovirax 200 mg Dispersible Tablets | Active Ingredients Aciclovir |
| Medicine Name Zovirax 200 mg/5 mL Oral Suspension | Active Ingredients Aciclovir |
| Medicine Name Zovirax 5% w/w Cream | Active Ingredients Aciclovir |
| Medicine Name Zovirax 800 mg Dispersible Tablets | Active Ingredients Aciclovir |
| Medicine Name Zovirax Double Strength Suspension | Active Ingredients Aciclovir |
| Medicine Name Zovirax IV 250mg | Active Ingredients Aciclovir sodium |
| Medicine Name Zyban 150 mg prolonged release tablets | Active Ingredients Bupropion Hydrochloride |
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 6 March 2019 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 28 February 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
Updated on 28 February 2019 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 6.1 - List of excipients
- Change to section 6.2 - Incompatibilities
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 20 June 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 20 June 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 19 January 2016 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.5 - Nature and contents of container
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
SPC:
Section 4.2 – updated dosing recommendation wording for clarity, minor typographical amendments
Section 4.8 – addition cross-reference to Section 4.4 (500mg tablet only)
Section 5.1 – updated Staphylococcus spp. resistance category
Section 5.2 – minor typographical amendments, alignment with QRD template
Section 5.3 – minor typographical amendments,
Section 6.5 - minor typographical amendments
Section 7 – IE MAH address change
Updated on 19 January 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 18 January 2016 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
- Change to improve clarity and readability
Updated on 16 July 2015 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 15 July 2015 PIL
Reasons for updating
- Change to date of revision
- Change to MA holder contact details
Updated on 13 March 2015 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 5.1 update to the Microbiological susceptibility table
Updated on 12 March 2015 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change to warnings or special precautions for use
- Change to side-effects
- Change to further information section
- Change to date of revision
Updated on 28 January 2014 SmPC
Reasons for updating
- Change due to harmonisation of SPC
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Change due to harmonisation or user testing of the patient leaflet
Updated on 27 January 2014 PIL
Reasons for updating
- Change due to harmonisation of PIL
- Change due to user-testing of patient information
Updated on 8 September 2011 PIL
Reasons for updating
- Change due to user-testing of patient information
Updated on 21 January 2010 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Summary of ZINNAT SPC CHANGES
125mg Tablets
1.name of the medicinal product
Zinnat 125mg Film-Coated Tablets 125mg
2.qualitative and QUantitative composition
Each tablet contains 125mg cefuroxime as cefuroxime axetil.
Excipients: Contains approximately 0.10 mg parahydroxybenzoates per tablet.
For a full list of excipients see section 6.1
Updated on 11 January 2010 PIL
Reasons for updating
- Change of trade or active ingredient name
- Change to storage instructions
Updated on 14 November 2007 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 Special Warnings and Precautions for Use
[…]
As with other antibiotics, prolonged use of cefuroxime may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of non-susceptible organisms (e.g. Candida, Enterococci and Clostridium difficile), which may require interruption of treatment.
[…]
4.8 Undesirable Effects
[…]
Infections and infestations
Common: Candida overgrowth from prolonged use.
[…]
Updated on 29 August 2007 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 27 September 2006 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.5 Interaction with Other Medicinal Products and Other Forms of Interaction
Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.
In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.
As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. This antibiotic does not interfere in the alkaline picrate assay for creatinine.
4.8............
Infections and infestations
Candida overgrowth from prolonged use............................
Updated on 28 March 2006 SmPC
Reasons for updating
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 3 July 2003 SmPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Product subject to medical prescription which may not be renewed (A)